Cohera Medical, B. Braun sign sales and distribution agreement for TissuGlu Surgical Adhesive

Cohera Medical, Inc.®, a leading innovator and developer of absorbable surgical adhesives and sealants, announced today that it has entered into an exclusive sales and marketing distribution agreement with B. Braun for its TissuGlu® Surgical Adhesive in Germany, Spain and Portugal.

The Agreement outlines a relationship between the two companies wherein B. Braun Surgical, S.A. will exclusively market and sell TissuGlu in the territories of Germany, Spain and Portugal through its existing Closure Technologies commercial teams. TissuGlu has been CE approved and for sale in Germany through a Cohera direct sales force since 2012 and has been used in over 2,000 surgical procedures since that time. TissuGlu is indicated in Europe for the approximation of tissue layers where subcutaneous dead space exists between tissue planes in large flap surgical procedures such as abdominoplasty.

"Cohera is excited to enter the relationship with B. Braun for the marketing of TissuGlu in these European countries," said Patrick Daly, Cohera Medical President and CEO. "We are looking forward to working with such a great organization and to making our breakthrough TissuGlu product available to more surgeons and patients in Europe."

TissuGlu is designed to meet surgeons' need for a strong, biocompatible, and easy-to-use surgical adhesive. TissuGlu is targeted for use in large flap procedures in which drains are used to control fluid output and seroma formation. TissuGlu is currently being utilized in Europe to eliminate drains or reduce complications in patients undergoing large flap surgical procedures such as abdominoplasty (tummy tuck), mastectomy, lymph node dissection, decubitus and latissimus dorsi flap procedures. Over 2,000 procedures have been conducted with TissuGlu bringing great benefit to patients, surgeons, and caregivers.

Source:

Cohera Medical, Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    B. Braun Melsungen AG. (2019, June 20). Cohera Medical, B. Braun sign sales and distribution agreement for TissuGlu Surgical Adhesive. News-Medical. Retrieved on April 19, 2024 from https://www.news-medical.net/news/20150121/Cohera-Medical-B-Braun-sign-sales-and-distribution-agreement-for-TissuGlu-Surgical-Adhesive.aspx.

  • MLA

    B. Braun Melsungen AG. "Cohera Medical, B. Braun sign sales and distribution agreement for TissuGlu Surgical Adhesive". News-Medical. 19 April 2024. <https://www.news-medical.net/news/20150121/Cohera-Medical-B-Braun-sign-sales-and-distribution-agreement-for-TissuGlu-Surgical-Adhesive.aspx>.

  • Chicago

    B. Braun Melsungen AG. "Cohera Medical, B. Braun sign sales and distribution agreement for TissuGlu Surgical Adhesive". News-Medical. https://www.news-medical.net/news/20150121/Cohera-Medical-B-Braun-sign-sales-and-distribution-agreement-for-TissuGlu-Surgical-Adhesive.aspx. (accessed April 19, 2024).

  • Harvard

    B. Braun Melsungen AG. 2019. Cohera Medical, B. Braun sign sales and distribution agreement for TissuGlu Surgical Adhesive. News-Medical, viewed 19 April 2024, https://www.news-medical.net/news/20150121/Cohera-Medical-B-Braun-sign-sales-and-distribution-agreement-for-TissuGlu-Surgical-Adhesive.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
B. Braun receives FDA approval to use 1g and 2g Ceftazidime in DUPLEX Drug Delivery System